JAK inhibitors in rheumatoid arthritis
JAK inhibitors in RA, including their safety.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 32, 20, 11, 15, 13.
All papers from the last 12 months
430 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Biomimetic nanosystem rewires microRNA-mediated inflammatory circuits and disrupts ROS crosstalk for multifaceted rheumatoid arthritis therapyBiomaterials2027 JanPMID 42472488
- Multi‑target mechanisms of paeoniflorin in inflammatory regulation: A network pharmacology (Review)Int J Mol Med2026 DecPMID 42852623Systematic review
- Integrative post-GWAS analysis prioritizes immune regulatory pathways and candidate effector signals in systemic lupus erythematosusJ Transl Autoimmun2026 DecPMID 42741480
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibitionJ Dermatolog Treat2026 DecPMID 42089250
- Preventing the inflammatory polarization of monocyte/macrophage provides an effective therapy for rheumatoid arthritis-associated vascular injuryInt Immunopharmacol2026 Nov 1PMID 42607529
- Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal AnalysisDrug Saf2026 NovPMID 42360669
- Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 StudiesRheumatol Ther2026 Oct 16PMID 42888330
- Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid ArthritisRheumatol Ther2026 Oct 15PMID 42879079
- Advances in the study of the role of bone immunity in physiological and pathological processes related to bone metabolismInt Immunopharmacol2026 Oct 15PMID 42546515Review
- Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: immunomodulation and antifibrotic therapy as complementary strategies?Respir Med2026 Oct 14PMID 42874937
More rheumatology trends
All specialties →Lung disease in systemic sclerosis
Interstitial lung disease in systemic sclerosis.
Giant cell arteritis and PMR
Giant cell arteritis, polymyalgia rheumatica and steroid-sparing treatment.
Key point: In PMR, interleukin-6 receptor blockers should be considered with glucocorticoids for relapsing disease and can be considered for new-onset high-risk patients.
Psoriatic arthritis
Psoriatic arthritis and its targeted treatments.
Gout
Gout management, including treat-to-target urate lowering.
Axial spondyloarthritis
Diagnosis and treatment of axial spondyloarthritis.
Myositis
Inflammatory myopathies, including dermatomyositis.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(JAK[tiab] OR tofacitinib[tiab] OR baricitinib[tiab] OR upadacitinib[tiab] OR filgotinib[tiab]) AND "rheumatoid arthritis"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.